{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:46Z","timestamp":1792448686481,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR051749"],"award-info":[{"award-number":["R01 AR051749"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.imbio.2025.152915","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:44:34Z","timestamp":1747755874000},"page":"152915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases"],"prefix":"10.1016","volume":"230","author":[{"given":"V. Michael","family":"Holers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2025.152915_bb0005","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.4049\/jimmunol.177.3.1904","article-title":"Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis","volume":"177","author":"Banda","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0010","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4049\/jimmunol.1102310","article-title":"Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice","volume":"188","author":"Banda","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/WNO.0000000000000508","article-title":"Neuromyelitis optica: deciphering a complex immune-mediated astrocytopathy","volume":"37","author":"Bennett","year":"2017","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.imbio.2025.152915_bb0020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/hemato3040040","article-title":"Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy","volume":"3","author":"Berentsen","year":"2022","journal-title":"Hemato"},{"key":"10.1016\/j.imbio.2025.152915_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molimm.2015.05.010","article-title":"L.A. T. C1q, antibodies and anti-C1q autoantibodies","volume":"68","author":"Beurskensa","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1078\/0171-2985-00141","article-title":"C1q, autoimmunity and apoptosis","volume":"205","author":"Botto","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.imbio.2025.152915_bb0035","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: Lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001107","article-title":"Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy","author":"Budding","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.imbio.2025.152915_bb0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/art.1780350109","article-title":"Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy","volume":"35","author":"Buyon","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2025.152915_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","article-title":"Regulation of humoral immunity by complement","volume":"37","author":"Carroll","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.imbio.2025.152915_bb0055","article-title":"The complement system and human autoimmune diseases","volume":"137","author":"Coss","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.imbio.2025.152915_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.immuni.2016.12.014","article-title":"Follicular dendritic cell activation by TLR ligands promotes autoreactive B cell responses","volume":"46","author":"Das","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.imbio.2025.152915_bb0065","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kid. Intl. Rep."},{"key":"10.1016\/j.imbio.2025.152915_bb0070","first-page":"211","article-title":"Granzyme K activates the entire complement cascade","volume":"641","author":"Donado","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0075","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4049\/jimmunol.168.3.1036","article-title":"Complement C4 is protective for lupus disease independent of C3","volume":"168","author":"Einav","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imbio.2025.152915_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","article-title":"Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice","volume":"65","author":"Elliott","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.imbio.2025.152915_bb0085","first-page":"10","article-title":"Development and optimization of an ELISA to quantitate C3(H2O) as a marker of human disease","author":"Elvington","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imbio.2025.152915_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01875","article-title":"The complement C3a and C3a receptor pathway in kidney diseases","author":"Gao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jha2.748","article-title":"Results of a phase 1\/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"4","author":"Gaya","year":"2023","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.imbio.2025.152915_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0952-7915(95)80029-8","article-title":"Structure and function of the pentraxins","volume":"7","author":"Gewurz","year":"1995","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0110","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"13","author":"Gharavi","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.imbio.2025.152915_bb0115","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils, but not activating Fcg receptors, are critical mediators of anti-phospholipid antibody-induced fetal loss","volume":"112","author":"Girardi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2025.152915_bb0120","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.imbio.2025.152915_bb0125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.imbio.2025.152915_bb0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","article-title":"Predictive power of the second renal biopsy in lupus nephritis: Significance of macrophages","volume":"59","author":"Hill","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.imbio.2025.152915_bb0135","first-page":"851","article-title":"Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis","volume":"70","author":"Huang","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.imbio.2025.152915_bb0140","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/35023175","article-title":"A role for the C3a anaphylatoxin receptor in the effector phase of asthma","volume":"406","author":"Humbles","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2025.152915_bb0145","first-page":"10","article-title":"Complement activation profile in myasthenia gravis patients: Perspectives for tailoring anti-complement therapy","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.imbio.2025.152915_bb0150","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3899\/jrheum.220752","article-title":"The role of complement in autoimmune disease-associated thrombotic microangiopathy and the potential for therapeutics","volume":"50","author":"Java","year":"2023","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imbio.2025.152915_bb0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne DRW, Merkel PS, Schall TJ, Bekker P, Group AS","year":"2021","journal-title":"NEJM"},{"key":"10.1016\/j.imbio.2025.152915_bb0160","first-page":"184","article-title":"The complement system and autoimmune diseases","volume":"8","author":"Jia","year":"2022","journal-title":"Chronic Dis. Trans. Med."},{"key":"10.1016\/j.imbio.2025.152915_bb0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/03009742.2021.1989814","article-title":"Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study","volume":"51","author":"Johansson","year":"2022","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.imbio.2025.152915_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/ki.2012.371","article-title":"Complement is crucial in the pathogenesis of ANCA-associated vasculitis","volume":"83","author":"Kallenberg","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.imbio.2025.152915_bb0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41586-020-2277-x","article-title":"Complement genes contribute sex-biased vulnerability in diverse disorders","volume":"582","author":"Kamitaki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2025.152915_bb0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/90686","article-title":"Contribution of the innate immune system to autoimmune myocarditis: a role for complement","volume":"2","author":"Kaya","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0185","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2025.152915_bb0190","first-page":"6","article-title":"ANCA-associated vasculitis","author":"Kitching","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.imbio.2025.152915_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/0-387-34134-X_6","article-title":"Self, non-self, and danger: a complementary view","volume":"586","author":"Kohl","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.imbio.2025.152915_bb0200","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.molimm.2008.01.036","article-title":"Complement receptor CR2\/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens","volume":"45","author":"Kuhn","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0205","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.4049\/jimmunol.1900620","article-title":"Targeting the immune complex-bound complement C3d ligand as a novel therapy for lupus","volume":"203","author":"Kulik","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2021.09.010","article-title":"Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies","volume":"140","author":"Le Stang","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0215","first-page":"10","article-title":"Expanding the role of complement therapies: the case for lupus nephritis","author":"Li","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.imbio.2025.152915_bb0220","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clim.2015.05.006","article-title":"Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease","volume":"160","author":"Lieberman","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0225","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aao4555","article-title":"C1q restrains autoimmunity and viral infection by regulating CD8+ T cell metabolism","volume":"360","author":"Ling","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.imbio.2025.152915_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic Lupus Erythematosus and Deficiencies of early Components of the Complement Classical Pathway","author":"Macedo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","article-title":"The role of complement in the development of systemic lupus erythematosus","volume":"22","author":"Manderson","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-025-02120-y","article-title":"\u2018Complement-ing\u2019 tissue inflammation via granzyme K?","author":"Mastellos","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0245","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41590-019-0503-1","article-title":"\u2018Stealth\u2019 corporate innovation: an emerging threat for therapeutic drug development","volume":"20","author":"Mastellos","year":"2019","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.imbio.2025.152915_bb0250","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.4049\/jimmunol.164.5.2281","article-title":"Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease","volume":"164","author":"Matsushita","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddmod.2014.08.002","article-title":"Lupus nephritis: animal modeling of a complex disease syndrome pathology","volume":"11","author":"McGaha","year":"2014","journal-title":"Drug Disc. Today Dis. Models"},{"key":"10.1016\/j.imbio.2025.152915_bb0260","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.4049\/jimmunol.1201621","article-title":"Absence of CD59 exacerbates systemic autoimmunity in MRL\/lpr mice","volume":"189","author":"Miwa","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0265","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(81)90882-5","article-title":"Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus","volume":"2","author":"Miyakawa","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.imbio.2025.152915_bb0270","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.imbio.2025.152915_bb0275","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semcdb.2017.06.009","article-title":"Molecular cell biology of complement membrane attack","volume":"72","author":"Morgan","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.imbio.2025.152915_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.600656","article-title":"An \u201coutside-in\u201d and \u201cinside-out\u201d consideration of complement in the multiple sclerosis brain: Lessons from development and neurodegenerative diseases","author":"Morgan","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.imbio.2025.152915_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.bi.57.070188.001541","article-title":"Molecular organization and function of the complement system","volume":"57","author":"Muller-Eberhard","year":"1988","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.imbio.2025.152915_bb0295","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.43.6.1167","article-title":"Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.imbio.2025.152915_bb0300","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1126\/science.118.3077.733","article-title":"The immune-adherence phenomenon","volume":"118","author":"Nelson","year":"1953","journal-title":"Science"},{"key":"10.1016\/j.imbio.2025.152915_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/962702","article-title":"Complement diagnostics: concepts, indications, and practical guidelines","volume":"2012","author":"Nilsson","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0310","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.imbio.2025.152915_bb0315","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.ekir.2021.08.005","article-title":"Long-term renal survival in antineutrophil cytoplasmic antibody\u2013associated glomerulonephritis with complement C3 deposition","volume":"6","author":"Oba","year":"2021","journal-title":"Kidney Intl. Rep."},{"key":"10.1016\/j.imbio.2025.152915_bb0320","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tibs.2020.04.004","article-title":"Emerging insights into the structure and function of complement C5a receptors","volume":"45","author":"Pandey","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.imbio.2025.152915_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2016.10.010","article-title":"Molecular imaging of the kidney in lupus nephritis to characterize response to treatment","volume":"182","author":"Parikh","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.imbio.2025.152915_bb0330","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1172\/JCI105272","article-title":"Immunofluorescent localization of immunoglobulins, complement, and fibrinogen in human diseases. I. Systemic lupus erythematosus","volume":"44","author":"Paronetto","year":"1965","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2025.152915_bb0335","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"NEJM"},{"key":"10.1016\/j.imbio.2025.152915_bb0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IJNRD.S129227","article-title":"Primary IgA nephropathy: current challenges and future prospects","volume":"11","author":"Penfold","year":"2018","journal-title":"Int. J. Neph. Renovasc. Dis."},{"key":"10.1016\/j.imbio.2025.152915_bb0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"NEJM"},{"key":"10.1016\/j.imbio.2025.152915_bb0350","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.imbio.2025.152915_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660194","article-title":"A family affair: addressing the challenges of factor H and the related proteins","author":"Poppelaars","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0360","first-page":"10","article-title":"The contribution of complement to the pathogenesis of IgA Nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?","author":"Poppelaars","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.imbio.2025.152915_bb0365","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.molimm.2012.07.002","article-title":"Human complement receptor 2 (CR2\/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE)","volume":"53","author":"R. A, Banda N, Szakonyi G, Chen XS, Holers VM.","year":"2013","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.imbio.2025.152915_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000236","article-title":"Cell-bound complement activation products in SLE","volume":"4","author":"Ramsey-Goldman","year":"2017","journal-title":"Lupus Sci. Med."},{"issue":"4","key":"10.1016\/j.imbio.2025.152915_bb0375","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01837363","article-title":"Mammalian lectins in activation and clearance mechanisms involving the complement system","volume":"15","author":"Reid","year":"1994","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.imbio.2025.152915_bb0380","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.0000000000000129","article-title":"Noninvasive detection of iC3b\/C3d deposits in the kidney using a novel bioluminescent imaging probe","volume":"34","author":"Renner","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.imbio.2025.152915_bb0385","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.imbio.2025.152915_bb0390","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.imbio.2012.07.014","article-title":"Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders","volume":"217","author":"Risitano","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.imbio.2025.152915_bb0395","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"NEJM"},{"key":"10.1016\/j.imbio.2025.152915_bb0400","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0961203311415561","article-title":"Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis","volume":"20","author":"Sato","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.imbio.2025.152915_bb0405","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ki.1989.83","article-title":"Physiological and pathological aspects of circulating immune complexes","volume":"35","author":"Schifferli","year":"1989","journal-title":"Kidney Int."},{"key":"10.1016\/j.imbio.2025.152915_bb0410","first-page":"329","article-title":"The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans","volume":"75","author":"Schifferli","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0415","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jid.2021.12.029","article-title":"C5aR2 deficiency ameliorates inflammation in murine epidermolysis bullosa acquisita by regulating Fc\u03b3 receptor expression on neutrophils","volume":"142","author":"Seiler","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.imbio.2025.152915_bb0420","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.4049\/jimmunol.166.10.6444","article-title":"Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL\/lpr mice","volume":"166","author":"Sekine","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0425","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.imbio.2025.152915_bb0430","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.imbio.2025.152915_bb0435","first-page":"33","article-title":"Complement C4A regulates autoreactive B cells in murine lupus","author":"Simoni","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.imbio.2025.152915_bb0440","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"JASN"},{"key":"10.1016\/j.imbio.2025.152915_bb0445","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1172\/JCI65861","article-title":"Detection of complement activation using monoclonal antibodies against C3d","volume":"123","author":"Thurman","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2025.152915_bb0450","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","author":"Vu","year":"2023","journal-title":"NEJM Evidence"},{"issue":"Suppl. 3","key":"10.1016\/j.imbio.2025.152915_bb0455","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1186\/ar586","article-title":"Complement and systemic lupus erythematosus","volume":"4","author":"Walport","year":"2002","journal-title":"Arth. Res. Ther."},{"key":"10.1016\/j.imbio.2025.152915_bb0460","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.imbio.2025.152915_bb0465","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/rheumatology\/kes218","article-title":"Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis","volume":"51","author":"Wang","year":"2012","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.imbio.2025.152915_bb0470","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B","volume":"164","author":"Watanabe","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0475","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1681\/ASN.2005040373","article-title":"C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice","volume":"16","author":"Wenderfer","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.imbio.2025.152915_bb0480","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.molimm.2008.12.004","article-title":"C3a receptor deficiency accelerates the onset of renal injury in the MRL\/lpr mouse","volume":"46","author":"Wenderfer","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0485","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.imbio.2025.152915_bb0490","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0952-7915(95)80028-X","article-title":"Structure, function and cellular expression of complement anaphylatoxin receptors","volume":"7","author":"Wetsel","year":"1995","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.imbio.2025.152915_bb0495","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"NEJM"},{"key":"10.1016\/j.imbio.2025.152915_bb0500","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/art.41011","article-title":"Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2025.152915_bb0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.imbio.2025.152915_bb0510","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-017-0417-9","article-title":"Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G","author":"Yao","year":"2017","journal-title":"Acta Neuropath Comm."},{"key":"10.1016\/j.imbio.2025.152915_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002079","article-title":"Association of genetic variants in complement factor H and factor H-related genes with systemic upus erythematosus susceptibility","author":"Zhao","year":"2011","journal-title":"PLoS Genet."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S017129852500049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S017129852500049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T20:10:50Z","timestamp":1751919050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S017129852500049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S017129852500049X"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2025.152915","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2025.152915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"152915"}}